Please assess the completion status of the following clinical trial:

Trial Title: Citalopram for Agitation in Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Probable Alzheimer's disease (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria), with Mini-Mental score of 5-28 inclusive~* A medication for agitation is appropriate, in the opinion of the study physician~* Clinically significant agitation for which either~  1. the frequency of agitation as assessed by the Neuropsychiatric Inventory (NPI) is 'Very frequently', or~ 2. the frequency of agitation as assessed by the NPI is 'Frequently' AND the severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked'~* Provision of informed consent for participation in the study by patient or surrogate (if necessary) and caregiver~* Availability of primary caregiver, who spends several hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study~* No change to Alzheimer's disease (AD) medications within the month preceding randomization, including starting, stopping, or dosage modifications~Exclusion criteria~* Meets criteria for Major Depressive Episode by Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV (TR)) criteria~* Presence of a brain disease that might otherwise explain the presence of dementia, such as extensive brain vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic brain injury, or multiple sclerosis~* Psychosis (delusions or hallucinations) requiring antipsychotic treatment in the opinion of the study physician~* Prolonged measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT interval)~* Treatment with citalopram is contraindicated in the opinion of the study physician~* Failure of past treatment with citalopram for agitation after adequate trial at a minimally accepted dose (greater than or equal to 20 mg/day)~* Treatment with a medication that would prohibit the safe concurrent use of citalopram, such as Monoamine oxidases (MAO) inhibitors~* Need for psychiatric hospitalization or suicidal~* Current participation in a clinical trial or in any study that may add a significant burden or affect neuropsychological or other study outcomes~* Current treatment with antipsychotics, anticonvulsants (other than dilantin), other antidepressants (other than trazodone, less than or equal to 50 mg per day at bedtime), benzodiazepines (other than lorazepam), or psychostimulants~* Any condition that, in the opinion of the study physician, makes it medically inappropriate or risky for the patient to enroll in the trial

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Citalopram and psychosocial intervention (Type: EXPERIMENTAL): Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
- Placebo and psychosocial intervention (Type: PLACEBO_COMPARATOR): Matching placebo, oral, and psychosocial intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).